RELAPSED

作品数：95被引量：150H指数：7
导出分析报告
相关领域：医药卫生农业科学更多>>
相关作者：关涛苏丽萍马莉赵瑾王晶荣更多>>
相关机构：上海市第一人民医院绍兴文理学院绍兴市人民医院浙江省人民医院更多>>
相关期刊：《Asian Journal of Andrology》《Journal of Integrative Medicine》《Open Journal of Blood Diseases》《Cellular & Molecular Immunology》更多>>
相关基金：国家自然科学基金北京市自然科学基金广东省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 期刊=Cancer Innovationx
共 条 记 录，以下是1-3
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Correction to“Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer”
《Cancer Innovation》2023年第4期318-318,共1页
Guan X,Ma F,Xu B.Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer.Cancer Innovation.2022;1-5...
关键词：BREAST RANDOMIZED METASTATIC 
Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases:A post hoc analysis of ALTER1202,a randomized,double-blind phase 2 study被引量：1
《Cancer Innovation》2023年第3期181-190,共10页Ying Cheng Qiming Wang Kai Li Jianhua Shi Baohui Han Lin Wu Gongyan Chen Jianxing He Jie Wang Haifeng Qin Xiaoling Li 
Province Development and Reform Commission,Grant/Award Numbers:2021C042-7,2021C043-1;Chia-tai Tianqing 264 Pharmaceutical Group Co.,Ltd;Provincial Health and Family Planning。
Background:The prognosis of patients with small cell lung cancer(SCLC)and brain metastases(BM)was poor.This study aimed to explore the efficacy and safety of anlotinib as third-line or above treatment in SCLC with BM....
关键词：anlotinib angiogenesis inhibitors brain metastasis advanced small cell lung cancer safety 
Pooled analyses of randomized controlled trials onpyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer
《Cancer Innovation》2022年第2期119-123,共5页Xiuwen Guan Fei Ma Binghe Xu 
National Nature Science Foundation of China,Grant/Award Number:8210114934;CAMS Innovation Fund for Medical Sciences,Grant/Award Numbers:CIFMS,2021-I2M-1-014。
Human epidermal growth factor receptor 2(HER2)-positive breast cancer,which accounts for 15%-20% of breast cancers,is associated with aggressive tumor behavior and conferred a poor outcome before the era of HER2-targe...
关键词：breast cancer tyrosine kinase inhibitor HER2-targeted therapy 
全选清除导出
共1页<1>
检索报告 对象比较 聚类工具 使用帮助 返回顶部